{"product_id":"anti-crispr-cas9-sp-rabbit-monoclonal-antibody-bha21008644","title":"Anti-CRISPR-Cas9 SP Rabbit Monoclonal Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis product is an anti-cas9 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ABCI-3; isotype Rabbit IgG; reactivity: Recombinant protein. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-CRISPR-Cas9 SP Rabbit Monoclonal Antibody catalog # M30929. Tested in WB, IHC, ICC\/IF, Flow Cytometry applications. This antibody reacts with Recombinant protein.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e cas9 (CRISPR-associated endonuclease Cas9\/Csn1).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone ABCI-3; isotype Rabbit IgG.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost:\u003c\/strong\u003e Rabbit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Recombinant protein (confirm in your model system with appropriate controls).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003ecas9 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): CRISPR (clustered regularly interspaced short palindromic repeat) is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids) (PubMed:21455174). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and this protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA; Cas9 only stabilizes the pre-crRNA:tracrRNA interaction and has no catalytic function in RNA processing (PubMed:24270795). Subsequently Cas9\/crRNA\/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer; Cas9 is inactive in the absence of the 2 guide RNAs (gRNA). The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. DNA-binding requires protein and both gRNAs, as does nuclease activity. Cas9 recognizes the protospacer adjacent motif (PAM) in the CRISPR repeat sequences to help distinguish self versus nonself, as targets within the bacterial CRISPR locus do not have PAMs. DNA strand separation and heteroduplex formation starts at PAM sites; PAM recognition is required for catalytic activity (PubMed:24476820). Confers immunity against a plasmid with homology to the appropriate CRISPR spacer sequences (CRISPR interference) (PubMed:21455174). . Reported cellular localization context: Cell membrane; Lipid-anchor, GPI-anchor. Tissue expression notes (as provided): Widely expressed. .\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eResearch context keywords from the source record include: Signaling Pathway.\u003c\/li\u003e\n\u003cli\u003eCurrent studies often focus on connecting target abundance\/localization to pathway perturbations across models, tissues, and cell states.\u003c\/li\u003e\n\u003cli\u003eQuantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eWestern blotting (WB):\u003c\/strong\u003e assess relative target abundance across samples, treatments, or time-points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e evaluate spatial distribution of target-positive staining in tissue architecture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence\/ICC (IF\/ICC):\u003c\/strong\u003e visualize subcellular localization patterns and cell-to-cell heterogeneity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlow cytometry:\u003c\/strong\u003e quantify target-positive populations and compare shifts in marker distributions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWorkflow ideas (metafield): Validate cas9 antibody specificity using KO\/KD control samples (WB\/IF\/IHC as appropriate), Detect cas9 expression by Western blot in cell or tissue lysates, Detect cas9 in FFPE tissue sections by immunohistochemistry, Localize cas9 by immunofluorescence\/immunocytochemistry in cultured cells, Quantify cas9-positive cells by flow cytometry in single-cell suspensions\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eConsider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.\u003c\/li\u003e\n\u003cli\u003eApparent molecular weight may vary by sample type and processing (observed MW: 50 kDa; calculated MW: 158441 MW).\u003c\/li\u003e\n\u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype, KO\/KD samples) and orthogonal validation when feasible.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eAdditional product details (from the source record)\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight (observed):\u003c\/strong\u003e 50 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCellular localization (provided):\u003c\/strong\u003e Cell membrane; Lipid-anchor, GPI-anchor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTissue details (provided):\u003c\/strong\u003e Widely expressed. .\u003c\/li\u003e\n\u003c\/ul\u003e \u003c!-- Sources (internal): - Antibodies — a laboratory manual overview — Cold Spring Harbor Protocols — https:\/\/cshprotocols.cshlp.org\/ - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Antibody validation and reproducibility — Nature methods (collections) — https:\/\/www.nature.com\/collections\/ - Immunohistochemistry\/Immunofluorescence basics — NIH \/ NCBI Bookshelf — https:\/\/www.ncbi.nlm.nih.gov\/books\/ --\u003e","brand":"Boster Bio","offers":[{"title":"100 uL\/vial \/ Unconjugated","offer_id":53071944352109,"sku":"M30929","price":370.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m30929-wb.jpg?v=1772618568","url":"https:\/\/www.ebiohippo.com\/products\/anti-crispr-cas9-sp-rabbit-monoclonal-antibody-bha21008644","provider":"BioHippo","version":"1.0","type":"link"}